VivoSeq
Other

Angiotensin Converting Enzyme

0

Pipeline Programs↗

1

Active Trials↗

1

Companies Involved↗

Angiotensin Converting Enzyme is an early-stage landscape with 0 programs across 1 company. The most active players are Apeiron Biologics.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Apeiron Biologics

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

13

clinical trials

Completed8 · 62%
Unknown status4 · 31%
Not yet recruiting1 · 8%

Clinical Trials

Trial Activity

13 trials

Angiotensin Converting Enzyme Inhibitors in Treatment of Covid 19
Not yet recruiting·TTanta University·Phase 3·NCT04345406·60 enrolled
Reversal of an Unfavorable Effect of Hydrochlorothiazide Compared to Angiotensin Converting Enzyme Inhibitor on Serum Uric Acid and Oxypurines Levels by Estrogen-progestin Therapy in Hypertensive Postmenopausal Women.
Completed·—·Phase 4·NCT03921736·180 enrolled
Angiotensin Converting Enzyme Inhibitors During Cardiopulmonary Bypass in Infants and Children
Completed·VVanderbilt University Medical Center·N/A·NCT00848250·21 enrolled
Impact of Angiotensin Converting Enzyme Activity on Exercise Training Sensitivity
Completed·UUniversity of Copenhagen·N/A·NCT03949075·52 enrolled
Safety and Tolerability Study of APN01 (Recombinant Human Angiotensin Converting Enzyme 2)
Completed·AApeiron Biologics·Phase 1·NCT00886353·22 enrolled
Increased Renal Oxygenation and Angiotensin Converting Enzyme Inhibition
Completed·IInstituto de Cardiologia do Rio Grande do Sul·Phase 4·NCT01545479·5 enrolled
Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery
Completed·UUniversity of Nebraska·Phase 4·NCT01669434·291 enrolled
Precision Treatment With Angiotensin Converting Enzyme Inhibitor
Completed·YYonsei University·Phase 4·NCT05535595·77 enrolled
The Influence of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Renal Function in Patients Undergoing Non-emergent Coronary Angiography
Completed·SSoroka University Medical Center·N/A·NCT01071642·100 enrolled
Changes After Angiotensin Converting Enzyme (ACE) Inhibitor Replacement by Angiotensin II Receptor Type I (AT1) Blocker
Unknown status·SSlovak Academy of Sciences·N/A·NCT01444833·35 enrolled
Effects of Angiotensin Converting Enzyme Inhibitors on Patency of Arterio-Venous Fistulas: A Randomized Controlled Trial
Unknown status·AArmed Forces Post Graduate Medical Institute (AFPGMI), Rawalpindi·Phase 1·NCT05132712·100 enrolled
The Use of Angiotensin Converting Enzyme Inhibitors and Incident Respiratory Infections, Are They Harmful or Protective?
Unknown status·UUniversity College, London·N/A·NCT04322786·1,302,508 enrolled
The Use of Ambulatory Blood Pressure Monitors to Assess Angiotensin Converting Enzyme Inhibitors
Unknown status·MMemorial Health University Medical Center·Phase 1·NCT02623036·20 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)